Medicover Polska facilities are testing the CarnaLife System application for remote patient health monitoring. MedApp S.A. software cares for chronically ill patients with diabetes and cardiac problems treated in selected Warsaw facilities of our partner.
The test implementation of the software at Medicover involves using the CarnaLife System application to remotely monitor chronically ill patients. Selected patients, from two diagnostic groups (diabetology and cardiology), received sets of devices which were chosen by the Medicover medical team (medical specialists and a coordinating nurse). This enabled remote diagnostics at the patients’ current location. In the whole process, patients equipped with peripherals can record their diagnostic data at any time and send them to the medical facility. Professionals at the facility can intervene if necessary. All results are interpreted by artificial intelligence (AI) algorithms. This provides specialists with information about abnormal events. Patients enjoy the comfort of contacting a specialist at any time safely via video consultation and receiving recommendations for their diagnostic process.
The first conclusions are as follows: a definite improvement in patient comfort, automation of treatment processes which translates into the efficiency of physicians’ and specialists’ work, reduction in the number of potential hospitalizations of chronically ill patients, reduction in the number of complications, convenience for physicians and patients alike, and more effective treatment.
You are welcome to watch the whole material:
Persons responsible for CarnaLife System implementation in Medicover facilities and for testing:
· Dr. n. med. Piotr Soszynski, Strategic Medical Advisory Director, Medicover
· Lek. med. Katarzyna Krysztopowicz-Sobura, Medicover
· Michał Adamczyk, Strategic Project Management Director, MedApp S.A.
We are glad that together with an exceptional partner, such as Medicover, we are creating the future of medicine, and the practical use of our application for remote patient monitoring, CarnaLife System, has been appreciated by experts, physicians and the patients themselves.
Read more See similar articles:
MedApp after Q4 2022: continued development of digital medicine technology solutions and acquisition of new sales contacts
As in the previous quarters of 2022, the Company is observing an extension of sales processes in the Polish market, trying to shift sales activity to foreign markets. To this end, the Company has signed further distribution agreements for the CarnaLife Holo solution
We are looking for companies and individuals interested in distributing MedApp’s medical technology.
CarnaLife Holo is a breakthrough technology for 3D visualization of imaged medical data which supports the planning and performance of medical procedures. With the help of Microsoft’s HoloLens 2, the physician can see in real space a three-dimensional hologram reflecting the structure of the imaged anatomical area.
MedApp after Q2 2022: Another Quarter of Geographic and Product Expansion
MedApp, a publicly listed company in the innovative medical technology industry, recorded net sales of PLN 1,588 million, PLN 878 thousand EBITDA earnings and PLN 405 thousand net profit in the second quarter of 2022, despite the increasing uncertainty in the business environment and the challenges facing medical facilities.